256 related articles for article (PubMed ID: 30037277)
21. Tumoral and stromal expression of MMP-2, MMP-9, MMP-14, TIMP-1, TIMP-2, and VEGF-A in cervical cancer patient survival: a competing risk analysis.
Azevedo Martins JM; Rabelo-Santos SH; do Amaral Westin MC; Zeferino LC
BMC Cancer; 2020 Jul; 20(1):660. PubMed ID: 32669083
[TBL] [Abstract][Full Text] [Related]
22. Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer.
Lin SY; Wang YY; Sheu WH
Clin Endocrinol (Oxf); 2003 Apr; 58(4):513-8. PubMed ID: 12641636
[TBL] [Abstract][Full Text] [Related]
23. Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer.
Ławicki S; Zajkowska M; Głażewska EK; Będkowska GE; Szmitkowski M
Onco Targets Ther; 2016; 9():911-9. PubMed ID: 26966379
[TBL] [Abstract][Full Text] [Related]
24. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
Gadducci A; Tana R; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
[TBL] [Abstract][Full Text] [Related]
25. Human Plasma Levels of VEGF-A, VEGF-C, VEGF-D, their Soluble Receptor - VEGFR-2 and Applicability of these Parameters as Tumor Markers in the Diagnostics of Breast Cancer.
Zajkowska M; Lubowicka E; Fiedorowicz W; Szmitkowski M; Jamiołkowski J; Ławicki S
Pathol Oncol Res; 2019 Oct; 25(4):1477-1486. PubMed ID: 30387014
[TBL] [Abstract][Full Text] [Related]
26. Serum matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in esophageal cancer patients.
Groblewska M; Mroczko B; Kozlowski M; Niklinski J; Laudanski J; Szmitkowski M
Folia Histochem Cytobiol; 2012; 50(4):590-8. PubMed ID: 23264224
[TBL] [Abstract][Full Text] [Related]
27. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.
Manenti L; Paganoni P; Floriani I; Landoni F; Torri V; Buda A; Taraboletti G; Labianca R; Belotti D; Giavazzi R
Eur J Cancer; 2003 Sep; 39(13):1948-56. PubMed ID: 12932675
[TBL] [Abstract][Full Text] [Related]
28. Squamous cell carcinoma antigen (SCC-Ag) during follow-up of cervical cancer patients: Role in the early diagnosis of recurrence.
Salvatici M; Achilarre MT; Sandri MT; Boveri S; Vanna Z; Landoni F
Gynecol Oncol; 2016 Jul; 142(1):115-119. PubMed ID: 27117922
[TBL] [Abstract][Full Text] [Related]
29. Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma.
Duk JM; Groenier KH; de Bruijn HW; Hollema H; ten Hoor KA; van der Zee AG; Aalders JG
J Clin Oncol; 1996 Jan; 14(1):111-8. PubMed ID: 8558185
[TBL] [Abstract][Full Text] [Related]
30. Expression and clinical significance of phosphoglycerate dehydrogenase and squamous cell carcinoma antigen in cervical cancer.
Jing Z; Heng W; Aiping D; Yafei Q; Shulan Z
Int J Gynecol Cancer; 2013 Oct; 23(8):1465-9. PubMed ID: 24247658
[TBL] [Abstract][Full Text] [Related]
31. [New tumour markers useful in diagnostics and monitoring of cervical cancer].
Bedkowska GE; Lawicki S; Szmitkowski M
Przegl Lek; 2007; 64(12):1022-7. PubMed ID: 18595508
[TBL] [Abstract][Full Text] [Related]
32. The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease.
Kotowicz B; Fuksiewicz M; Jonska-Gmyrek J; Bidzinski M; Kowalska M
Tumour Biol; 2016 Jan; 37(1):1271-8. PubMed ID: 26289850
[TBL] [Abstract][Full Text] [Related]
33. Correlation Between Squamous Cell Carcinoma Antigen Level and the Clinicopathological Features of Early-Stage Cervical Squamous Cell Carcinoma and the Predictive Value of Squamous Cell Carcinoma Antigen Combined With Computed Tomography Scan for Lymph Node Metastasis.
Xu D; Wang D; Wang S; Tian Y; Long Z; Ren X
Int J Gynecol Cancer; 2017 Nov; 27(9):1935-1942. PubMed ID: 28914639
[TBL] [Abstract][Full Text] [Related]
34. Pretreatment plasma levels and diagnostic utility of hematopoietic cytokines in cervical cancer or cervical intraepithelial neoplasia patients.
Ławicki S; Będkowska GE; Gacuta-Szumarska E; Knapp P; Szmitkowski M
Folia Histochem Cytobiol; 2012 Jul; 50(2):213-9. PubMed ID: 22763962
[TBL] [Abstract][Full Text] [Related]
35. [Expressions of receptor-binding cancer antigen expressed on SiSo cells, vascular endothelial growth factor, and matrix metalloproteinase-9 in cervical carcinoma and correlation thereof with the invasion and metastasis of the cancerous tissues].
Liu R; Pu DM; Cheng YX; Yin L
Zhonghua Yi Xue Za Zhi; 2007 May; 87(19):1326-9. PubMed ID: 17727777
[TBL] [Abstract][Full Text] [Related]
36. [Significance and implication on changes of serum squamous cell carcinoma antigen in the diagnosis of recurrence squamous cell carcinoma of cervix].
Li Q; Liu S; Liu H; Zhang J; Guo S; Wang L
Zhonghua Fu Chan Ke Za Zhi; 2015 Feb; 50(2):131-6. PubMed ID: 25877611
[TBL] [Abstract][Full Text] [Related]
37. Application of tumor markers SCC-Ag, CEA, and TPA in patients with cervical precancerous lesions.
Farzaneh F; Shahghassempour S; Noshine B; Arab M; Yaseri M; Rafizadeh M; Alizadeh K
Asian Pac J Cancer Prev; 2014; 15(9):3911-4. PubMed ID: 24935573
[TBL] [Abstract][Full Text] [Related]
38. Plasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers.
Będkowska GE; Gacuta E; Zajkowska M; Głażewska EK; Osada J; Szmitkowski M; Chrostek L; Dąbrowska M; Ławicki S
J Ovarian Res; 2017 Jun; 10(1):39. PubMed ID: 28662671
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of serum CA-125 and soluble tumor necrosis factor receptor type I in cervical adenocarcinoma patients.
Kotowicz B; Kaminska J; Fuksiewicz M; Kowalska M; Jonska-Gmyrek J; Gawrychowski K; Sobotkowski J; Skrzypczak M; Starzewski J; Bidzinski M
Int J Gynecol Cancer; 2010 May; 20(4):588-92. PubMed ID: 20686378
[TBL] [Abstract][Full Text] [Related]
40. The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients.
Mroczko B; Groblewska M; Okulczyk B; Kedra B; Szmitkowski M
Int J Colorectal Dis; 2010 Oct; 25(10):1177-84. PubMed ID: 20556397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]